Clinical trial
A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)
NCT03437304 is registered in ClinicalTrials.gov with Eurocine Vaccines AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)
- Lead sponsor
- Eurocine Vaccines AB
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 9, 2018
- Completion date
- November 30, 2018
- Enrollment
- 298 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
influenza